The Relationship Between Insulin Resistance and Liver Damage in Non-alcoholic Fatty Liver Patients

Overview

Journal Sisli Etfal Hastan Tıp Bul

Specialty General Medicine

Date 2020 Dec 28

PMID 33364879

Citations 7

Authors

Elif Guven Cetin

Nazan Demir

Ilker Sen

Affiliations

Soon will be listed here.

Abstract

Objectives: Non-alcoholic fatty liver disease (NAFLD) is closely associated with diseases, such as obesity, diabetes mellitus, metabolic syndrome, which are characterized by insulin resistance. NAFLD is thought to be a manifestation of metabolic syndrome in the liver. Liver fibrosis has a high prognostic significance in non-alcoholic steatohepatitis (NASH). In this study, the relationship between insulin resistance and the histopathological changes in the liver was investigated in biopsy-proven NAFLD patients.

Methods: In this study, 85 biopsy-proven NAFLD patients (64 NASH, 21 non-NASH) and 40 healthy control subjects were enrolled. Insulin resistance was calculated using the "homeostasis model assessment of insulin resistance" (HOMA-IR).

Results: C reactive protein, total cholesterol, low-density lipoprotein, triglyceride, body mass index (BMI), HOMA-IR levels were significantly higher in the NAFLD group compared to the control group. In the NASH group, the HOMA-IR level was significantly higher than the non-NASH group (p=0.026). When NAFLD patients with advanced fibrosis (stage 3-4, n=27) and without fibrosis (stage 0-2, n=58) are compared, in advanced fibrosis group BMI (35.2±4.6 kg/m and 32.7±4.1 kg/m, respectively; p=0.031) and HOMA-IR (6.3 [5.8-6.8] and 3.4 [2.6-4.8], respectively, p=0.001) levels were higher significantly. In the covariance analysis, when confounding factors, such as BMI, age and gender, were corrected, it was observed that the elevation of HOMA-IR level in the advanced fibrosis group continued statistically significantly.

Conclusion: HOMA-IR levels were high in NAFLD patients with advanced fibrosis. HOMA-IR, which can be easily measured in daily practice, is an independent predictor for fibrosis.

Citing Articles

Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and mortality among survivors of liver cirrhosis: a prospective cohort study.

Fotros D, Hekmatdoost A, Pashayee-Khamene F, Karimi S, Ahmadzadeh S, Saberifiroozi M Nutr J. 2025; 24(1):15.

PMID: 39856705 PMC: 11762518. DOI: 10.1186/s12937-025-01086-9.

Does Online Social Support Affect the Eating Behaviors of Polish Women with Insulin Resistance?.

Pastusiak K, Kregielska-Narozna M, Mroz M, Seraszek-Jaros A, Blazejewska W, Bogdanski P Nutrients. 2024; 16(20).

PMID: 39458504 PMC: 11510215. DOI: 10.3390/nu16203509.

Propylthiouracil Induced Rat Model Reflects Heterogeneity Observed in Clinically Non-Obese Subjects with Nonalcoholic Fatty Liver Disease.

Jin Y, Liu Q, Wang Y, Wang B, An J, Chen Q Int J Mol Sci. 2024; 25(19).

PMID: 39409093 PMC: 11477315. DOI: 10.3390/ijms251910764.

Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease.

Laeeq T, Tun K Clin Liver Dis (Hoboken). 2024; 23(1):e0181.

PMID: 38831769 PMC: 11146514. DOI: 10.1097/CLD.0000000000000181.

Metformin and the Liver: Unlocking the Full Therapeutic Potential.

Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, DAvino M Metabolites. 2024; 14(4).

PMID: 38668314 PMC: 11052067. DOI: 10.3390/metabo14040186.

References

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M . High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001; 34(4 Pt 1):738-44. DOI: 10.1053/jhep.2001.28055. View

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

Bugianesi E, Manzini P, DAntico S, Vanni E, Longo F, Leone N . Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004; 39(1):179-87. DOI: 10.1002/hep.20023. View

Bugianesi E, McCullough A, Marchesini G . Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005; 42(5):987-1000. DOI: 10.1002/hep.20920. View

Milic S, Lulic D, Stimac D . Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014; 20(28):9330-7. PMC: 4110564. DOI: 10.3748/wjg.v20.i28.9330. View

Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J . Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2009; 51(2):595-602. DOI: 10.1002/hep.23314. View

Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. DOI: 10.1002/hep.21327. View

Hanley A, Williams K, Festa A, Wagenknecht L, DAgostino Jr R, Haffner S . Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54(11):3140-7. DOI: 10.2337/diabetes.54.11.3140. View

10.

Shields W, Thompson K, Grice G, Harrison S, Coyle W . The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2010; 2(3):157-63. PMC: 3002518. DOI: 10.1177/1756283X09105462. View

11.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

12.

Fracanzani A, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E . Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008; 48(3):792-8. DOI: 10.1002/hep.22429. View

13.

Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F . Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut. 2007; 56(9):1296-301. PMC: 1954981. DOI: 10.1136/gut.2006.107946. View

14.

Brunt E . Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol. 2006; 22(4):330-8. DOI: 10.1053/j.semdp.2006.04.002. View

15.

Baran B, Akyuz F . Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?. World J Gastroenterol. 2014; 20(39):14219-29. PMC: 4202350. DOI: 10.3748/wjg.v20.i39.14219. View

16.

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107(6):811-26. DOI: 10.1038/ajg.2012.128. View

17.

Park S, Kim B, Yun J, Kim J, Park D, Cho Y . Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004; 19(6):694-8. DOI: 10.1111/j.1440-1746.2004.03362.x. View

18.

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S . Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48(4):634-42. DOI: 10.1007/s00125-005-1682-x. View

19.

Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A . Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2015; 63(1):107-16. DOI: 10.1002/hep.28287. View

20.

McCullough A . Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006; 40 Suppl 1:S17-29. DOI: 10.1097/01.mcg.0000168645.86658.22. View